Abstract
The FDA issued draft guidance to help pharmaceutical companies and researchers identify an optimal dose of an investigational agent instead of determining its maximum tolerated dose. The recommendations cover collecting and interpreting data, trial design, safety monitoring, premarket dosing, and future indications.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
